Breaking News
13 hours ago
Vaibhavi M.
Regeneron and Sanofi gain Japan approval for Dupixent in bullous pemphigoid, showing improved remission in Phase 2/3 trial for moderate-to-severe autoimmune skin disease.
Vaibhavi M.
Amylyx Pharmaceuticals completes Phase 3 enrollment for avexitide in post-bariatric hypoglycemia, advancing Breakthrough Therapy-designated drug with topline data expected in Q3 2026.
Vaibhavi M.
Ocugen reports Phase 2 success for OCU410 gene therapy in geographic atrophy, showing reduced lesion growth and advancing toward Phase 3 trial for dry age-related macular degeneration.
Vaibhavi M.
Thermo Fisher Scientific completes $8.9B acquisition of Clario to enhance clinical trial data solutions, strengthening biopharma services and accelerating drug development analytics capabilities.
Vaibhavi M.